Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
RESEARCH TOOLSreports
Holding AUPH?
Track your performance easily
AUPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.71 - $9.74
Previous Close$8.77
Volume1.60M
Average Volume (3M)1.24M
Market Cap
$1.26B
Enterprise Value$994.79M
Total Cash (Recent Filing)$348.75M
Total Debt (Recent Filing)$87.85M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 04, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding142,990,974
10 Day Avg. Volume1,814,963
30 Day Avg. Volume1,237,286
Standard Deviation0.31
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.04
Price to Sales (P/S)5.28
Price to Cash Flow (P/CF)17.10
P/FCF Ratio16.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.51
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda-114.78
Forecast
1Y Price Target
$10.96Price Target Upside23.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
PremiumCompany Announcements
Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
PremiumCompany Announcements
Aurinia Pharmaceuticals Engages at London Conference
PremiumCompany Announcements
Aurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring
PremiumCompany Announcements
Aurinia Pharmaceuticals Reports Strong Q3 Growth and RestructuringBulls Say, Bears Say
Bulls Say
Financial PerformanceAurinia reported third consecutive revenue beat this year with Lupkynis net product revenue incrementally above consensus, reinforcing confidence in achieving or possibly exceeding the net product revenue guidance of $210-220M.
Regulatory ApprovalAurinia announced that the Japanese Health Authorities have approved Lupkynis for the treatment of lupus nephritis, leading to an additional $10M milestone payment and potential royalties up to 20% on future sales in Japan.
Strategic OpportunitiesThe approval of Lupkynis in Japan could pave the way for an acquisition of Aurinia by Otsuka, marking a significant strategic development for the company.
Bears Say
Patent ProtectionThe longevity of the Lupkynis patent protection in the U.S. remains an uncertainty with maximum composition of matter patent term extension ending in October 2027.
Revenue And Market RisksKey risks to the price target include revenue growth below guidance or significantly below expectations, unforeseen safety issues, and IP challenges that reduce market exclusivity.
Strategic OpportunitiesAnalyst expresses disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.
---
Ownership Overview
2.77% Insiders
5.29% Mutual Funds
17.34% Other Institutional Investors
68.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $4.71 and its highest was $9.74 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.015 by $0.085.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is $0.03.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 143,179,280 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.015. Following the earnings report the stock price went up 10.904%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
---
Aurinia Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.96 (23.70% Upside)
$10.96 (23.70% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 95%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.99%
12-Months-Change
Fundamentals
Return on Equity
-5.78%
Trailing 12-Months
Asset Growth
-1.02%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
AUPH Earnings Call
Q3 2024
0:00 / 0:00
---
AUPH Revenue Breakdown
90.33% Product revenue, net
9.67% License and contract revenue
---
AUPH Stock 12 Month Forecast
Average Price Target
$10.96
▲(23.70% Upside)
Technical Analysis
Best Analysts Covering AUPH
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+30.68%
reiterated a buy rating 12 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +30.68% per trade.
---